Related Experiment Video
Updated: Aug 19, 2025
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
MiR-181a-2-3p as a potential diagnostic and prognostic marker for myelodysplastic syndrome
Xiaolin Liang1,2, Zeyan Shi1,2, Xiaoke Huang1
1Hematology Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People's Republic of China.
Objective:
Myelodysplastic syndrome (MDS) is a clonal bone marrow disorder with a high propensity to develop into acute myeloid leukemia (AML). Although abnormal microRNA expression has been implicated in MDS, the exact role of miR-181a-2-3p has not been entirely elucidated. Here, we investigated miR-181a-2-3p levels in bone marrow (BM), and described its utility as a potential indicator for MDS diagnosis and prognosis.
Methods:
We evaluated miR-181a-2-3p expression in BM samples of 54 newly diagnosed MDS cases, 16 sAML patients and 32 healthy donors and then assessed its association with clinical characteristics and its potential value for MDS diagnosis and prognosis.
Results:
Compared with healthy controls, miR-181a-2-3p levels were decreased in the total cohort of MDS patients. Additionally, in MDS patients with secondary AML (sAML), miR-181a-2-3p was over-expressed relative to levels in those without this form. The areas under the curve of receiver operating characteristic curves were 0.700 and 0.750 to distinguish MDS patients from controls and sAML from newly diagnosed MDS, respectively. Kaplan-Meier analysis showed a positive correlation between miR-181a-2-3p expression and overall survival (OS). Further, multivariate analysis indicated that miR-181a-2-3p was an independent prognostic index for MDS with respect to OS.
Conclusion:
Decreased miR-181a-2-3p expression in MDS patients may be considered as one of the underlying markers reflecting MDS progression and prognosis.
Insights
Levels of miR-181a-2-3p are decreased in myelodysplastic syndrome (MDS) patients, but elevated in those who develop secondary acute myeloid leukemia (sAML). This microRNA serves as a potential diagnostic and prognostic indicator for MDS.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Myelodysplastic syndrome (MDS) is a bone marrow disorder with a high risk of progressing to acute myeloid leukemia (AML).
- Aberrant microRNA expression is implicated in MDS pathogenesis, but the specific role of miR-181a-2-3p remains unclear.
Purpose of the Study:
- To investigate miR-181a-2-3p expression levels in bone marrow (BM) of MDS patients.
- To evaluate the diagnostic and prognostic utility of miR-181a-2-3p in MDS.
Main Methods:
- Quantitative assessment of miR-181a-2-3p expression in BM samples from 54 MDS patients, 16 secondary AML (sAML) patients, and 32 healthy donors.
- Correlation analysis with clinical characteristics, receiver operating characteristic (ROC) curve analysis for diagnostic accuracy, and Kaplan-Meier analysis for survival prediction.
Main Results:
- miR-181a-2-3p levels were significantly decreased in MDS patients compared to healthy controls.
- miR-181a-2-3p was over-expressed in MDS patients who progressed to sAML.
- ROC analysis demonstrated potential for distinguishing MDS from controls (AUC=0.700) and sAML from MDS (AUC=0.750).
- Kaplan-Meier analysis revealed a positive correlation between miR-181a-2-3p expression and overall survival (OS).
- Multivariate analysis confirmed miR-181a-2-3p as an independent prognostic factor for OS in MDS.
Conclusions:
- Decreased miR-181a-2-3p expression in MDS may reflect disease progression.
- miR-181a-2-3p holds promise as a biomarker for MDS diagnosis and prognosis, particularly for predicting overall survival.
More Related Videos
08:14MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018